CD274 and hepatocellular carcinoma: Besides, combination therapy against different targets showed promising improved immunotherapy response rates, and a recent study showed that a combination of atezolizumab (an anti-PD-L1 inhibitor) with bevacizumab (an anti-VEGFR inhibitor) led to enhancing antitumor activity and safety for patients with unresectable hepatocellular carcinoma [69].